A theory about how the brain might heal, built from five categories of intervention that each have real research behind them individually, and the open question of what happens when you combine all five.
This is not a summary of one specific published study. It's a theory built by looking at five categories of intervention, metabolic, movement, lifestyle, supplement, and peptide, that each have real, individually-documented research behind them in the context of brain aging and Alzheimer's-like pathology, most of it in preclinical (animal) models rather than human trials. The open, honest question this page explores is what combining all five at once might do, not a claim that combining them has been proven to do anything specific.
Each pillar below is grounded in real preclinical or early-stage research on its own. What hasn't been tested, and what this page does not claim has been tested, is stacking all five simultaneously in a single controlled study. The reasoning behind the theory: Alzheimer's-like pathology involves multiple overlapping mechanisms (metabolic dysfunction, inflammation, impaired protein clearance, synaptic loss), so an intervention that only targets one mechanism may be addressing a small piece of a larger problem. Combining interventions that each target a different mechanism is a reasonable hypothesis worth taking seriously, and also, honestly, unproven as a combination.
This isn't about picking one intervention and pushing it hard. The theory runs all five simultaneously. That's the thesis: dementia-like pathology is multi-factorial, so a meaningful approach probably has to be multi-factorial too, even though the combination itself hasn't been tested.
Ketogenic diet (80% fat) + 18:6 intermittent fasting. Shifts the brain to ketone fuel, suppresses insulin resistance, triggers autophagy, and reduces amyloid production at the source. This is the foundation, everything else builds on it.
Aerobic training 5x/week + resistance training 3x/week. Promotes BDNF, mitochondrial biogenesis, and glucose uptake in the brain. This framework weights it equally to the compounds, not optional.
7–9 hours of quality sleep on a consistent light/dark cycle + stress management (environmental enrichment). Cortisol suppression matters. Sleep is when the brain's glymphatic system clears amyloid waste.
Ten compounds supporting anti-inflammation, mitochondrial function, methylation, NAD+ production, acetylcholine, and nerve growth. All available without a prescription with independent research support.
Seven injectable peptides targeting neurotrophic support, mitochondrial protection, metabolic signaling, and tissue repair. The most advanced tier, all investigational for these uses. Requires physician involvement.
These ten compounds have the most accessible entry point. No prescriptions, no injections. Each targets a specific failure mode in the Alzheimer's cascade. Evidence ratings below are for educational reference only.
EPA and DHA are the brain's preferred omega-3 fatty acids. They reduce neuroinflammation, support membrane fluidity, and protect against Aβ-induced toxicity. The Omega-3 Index (target: 8–12%) is a measurable biomarker you can track with labs. Independent human research on omega-3s and cognitive aging is robust.
Vitamin D receptors are found throughout the brain. Deficiency is associated with accelerated cognitive decline and increased dementia risk. It modulates immune function, reduces neuroinflammation, and supports calcium homeostasis. Test serum 25-OH-D before starting high-dose supplementation, target range 60–80 ng/mL for most optimization protocols. Note: 10,000 IU/day is above standard recommendations; discuss with your doctor.
This is the only magnesium form clinically shown to meaningfully raise brain magnesium levels (other forms raise serum Mg but don't cross the blood-brain barrier as effectively). Higher brain magnesium correlates with improved synaptic density and cognitive flexibility. Human trials at MIT showed meaningful improvements in older adults. The threonate compound was specifically designed for CNS delivery.
Elevated homocysteine is an independent risk factor for dementia, and these three B vitamins are the primary drivers of homocysteine reduction. B12/folate/B6 work together in the methylation cycle. The Oxford B-vitamin trials showed meaningful slowing of brain atrophy in people with elevated homocysteine. This is arguably the most overlooked metabolic lever in cognitive health. Get your homocysteine tested, target under 8 µmol/L.
Nicotinamide Mononucleotide is a direct NAD+ precursor. NAD+ levels decline with age and are critical for sirtuin activity, the proteins that regulate cellular repair, mitochondrial function, and DNA maintenance. Animal models consistently show cognitive and metabolic benefits. Human trials are accumulating. The protocol also references direct NAD+ IV dosing (50mg every other day) as an alternative/addition to oral NMN.
Coenzyme Q10 sits at the heart of the mitochondrial electron transport chain and is a fat-soluble antioxidant. Brain tissue is metabolically dense, highly vulnerable to oxidative stress. CoQ10 levels decline with age. The ubiquinol form (reduced CoQ10) is better absorbed than ubiquinone. This is particularly relevant for anyone on statins, which deplete CoQ10.
Alpha-GPC is a choline compound that readily crosses the blood-brain barrier and serves as the most bioavailable precursor to acetylcholine, the neurotransmitter most depleted in Alzheimer's. European countries use it as a prescription drug for cognitive decline. It's sold OTC in the US. Human trials in mild cognitive impairment and Alzheimer's patients show meaningful improvements in cognitive function.
Hericium erinaceus contains hericenones and erinacines, compounds shown to stimulate Nerve Growth Factor (NGF) synthesis. NGF supports the survival and maintenance of neurons. A double-blind human trial published in Phytotherapy Research showed significant cognitive improvement in adults with mild cognitive impairment at 3g/day. Effects appear to reverse when supplementation stops, suggesting it requires consistent use.
This is the most misunderstood item on the oral/transdermal list. Nicotine, isolated from tobacco, is a nicotinic acetylcholine receptor agonist with documented cognitive enhancement properties. Epidemiological studies noted for decades that smokers had lower Alzheimer's rates, eventually pointing to nicotine's cholinergic mechanism rather than tobacco itself. Vanderbilt trials explored nicotine patches specifically for mild cognitive impairment. This is not an endorsement of tobacco or smoking. For non-smokers, nicotine introduces dependency risk, this requires careful, physician-supervised consideration.
Regulatory Note: All peptides in this section are administered by subcutaneous or intramuscular injection. None have FDA approval for the cognitive or metabolic uses described in this framework. They are investigational compounds. This information is provided for educational transparency only. BritePear does not recommend, source, or sell these compounds. Pursuing any injectable peptide protocol requires physician involvement.
Body Protection Compound-157. A synthetic 15-amino-acid peptide derived from a gastric protein. Extensively studied in animal models for gut healing, angiogenesis (new blood vessel formation), tendon/ligament repair, and gut-brain axis regulation. It promotes nitric oxide synthesis and has shown neuroprotective properties in rodent models. No completed human clinical trials as of this writing, though it's one of the most commonly self-administered research peptides globally.
Glycine-Histidine-Lysine copper complex. A naturally occurring human plasma peptide that declines significantly with age. Used extensively in topical skincare for wound healing and collagen synthesis, that's the well-established use. Systemically, it has shown anti-inflammatory, antioxidant, and potentially neurotrophic effects in preclinical models. Research by Dr. Loren Pickart spans several decades. Injectable systemic use is investigational.
Mitochondrial Open Reading Frame of the 12S rRNA-c. A mitochondria-derived peptide that functions as a metabolic hormone, it activates AMPK, improves insulin sensitivity, and has shown anti-aging effects in animal models. Described as a "mitokine" because it signals from the mitochondria to the rest of the cell and body. Animal data on cognitive and metabolic function is promising. Currently no approved human uses.
SS-31 is a mitochondria-targeted peptide that binds to cardiolipin, a critical phospholipid in the inner mitochondrial membrane. It reduces oxidative stress directly at the site of production and has been in Phase II/III clinical trials for heart failure (Stealth BioTherapeutics). More human data exists for this compound than most others on this list. Preclinical data across neurodegeneration, cardiac, and renal models is extensive.
A synthetic ACTH(4-7) analog developed in Russia. It upregulates BDNF (brain-derived neurotrophic factor) and has been studied in Russia and Eastern Europe for stroke recovery, cognitive enhancement, and optic nerve disease. Used clinically in Russia and Ukraine. Available there by prescription. In the US it's a research compound. The nasal spray form is the most commonly discussed route; this framework specifies subcutaneous injection.
Cerebrolysin is a hydrolyzed porcine brain peptide mixture that mimics the effects of endogenous neurotrophic factors (BDNF, NGF, CNTF). It's been in clinical use for Alzheimer's and stroke in Europe and Asia for over 30 years. Administered intramuscularly or intravenously. Meta-analyses show meaningful cognitive improvement in Alzheimer's patients. Not FDA-approved in the US, but arguably has more human clinical data than any other peptide on this list.
Retatrutide is a triple agonist, GLP-1, GIP, and glucagon receptors simultaneously. It's in the same family as semaglutide and tirzepatide but adds the glucagon receptor component for additional metabolic benefit. Phase 2 human trials showed remarkable weight loss outcomes. Its inclusion here is for its metabolic and potentially neuroprotective effects, GLP-1 receptor activation is associated with reduced neuroinflammation and amyloid burden. As of this writing, retatrutide is not FDA-approved and not available for clinical prescribing. Any source claiming to provide it is operating outside regulatory approval.
A theoretical implementation guide, organized by time of day. This is a framework to bring to a provider, not a personal prescription.
These are the biomarkers the research protocol tracked at weeks 0, 13, and 26. Think of this as the measurement framework, what you'd want to baseline before starting anything.
When I first came across this framework, my initial reaction was skepticism. A theory with dramatic, precisely-numbered claims, attached to a website selling coaching, is a red flag pattern I've learned to notice, and when I went looking for the actual underlying study, I couldn't find one. That matters, and I'm not going to pretend it doesn't.
But here's what I keep coming back to: the individual mechanisms aren't exotic. Ketosis suppressing amyloid. Omega-3s reducing neuroinflammation. B vitamins lowering homocysteine. Magnesium threonate improving synaptic density. These aren't fringe claims, they're grounded in years of independent research, mostly in animal models. What this page proposes is stacking them all simultaneously, a real, testable hypothesis about what might happen when you attack the problem from every angle at once, not a claim that anyone has actually run that test.
The peptide tier, that's a different conversation. Cerebrolysin has actual human trial data. SS-31 has been in Phase III trials. Semax is prescribed in Russia. Retatrutide is real and in active development. The idea that these compounds could have neuroprotective value isn't wild, the question is whether the combination, at these doses, translates from a mouse to a person. That answer doesn't exist yet.
What I take from this isn't a protocol to follow. It's a map of mechanisms, a way of thinking about brain health as something that happens across five pillars simultaneously, not a pill you add to a bad diet and a sedentary life. That part I'm confident in. And most of Pillar 4 is already in my routine for exactly these reasons.
This page is a theory, not a report: five intervention categories, metabolic reset, movement, lifestyle, supplements, and peptides, each with real individual research behind them, combined into a framework for what might address Alzheimer's-like pathology from multiple angles at once. The combination itself hasn't been tested anywhere, in mice or in people.
The catch: even the individual pillars are mostly preclinical (animal) evidence, not human trials, and the most advanced tier, the seven injectable peptides, are all investigational, without FDA approval for these uses.
What's immediately actionable: the metabolic foundation (keto + fasting), the movement protocol, the sleep discipline, and most of the oral supplement stack are all well-supported independently. The peptide tier requires physician involvement and realistic expectations about the evidence base.
The real lesson isn't any single compound. It's that brain health is multivariate, and if you're only pulling one lever, you're probably leaving most of the benefit on the table.